Acorda Therapeutics, Inc. (Nasdaq: ACOR)
announced today that it will report its financial results for the second
quarter 2009 on Tuesday, August 4, 2009 at 8:30 a.m. ET before the U.S.
financial markets open.
In conjunction with the press release, the Company will also host a
conference call and live audio webcast at 8:30 a.m. ET on Tuesday,
August 4, 2009 to discuss the Company's financial results for the second
quarter 2009.
To participate in the conference call, please dial 866-804-6925
(domestic) or 857-350-1671 (international) and reference the access code
65868262. The presentation will be available via a live webcast at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=194451&eventID=2331061.
A replay of the call will be available from 11:30 a.m. ET on August 4,
2009 until midnight on September 3, 2009. To access the replay, please
dial 888-286-8010 (domestic) or 617-801-6888 (international) and
reference the access code 68339805. The archived webcast will be
available for 30 days in the Investor Relations section of the Acorda
website at http://www.acorda.com.
About
Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for
spinal cord injury, multiple sclerosis and related nervous system
disorders. The Company's marketed products include Zanaflex Capsules®
(tizanidine hydrochloride), a short-acting drug for the management of
spasticity. The Company's pipeline includes a number of products in
development for the treatment, regeneration and repair of the spinal
cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including delays in obtaining or failure to obtain FDA approval of
Fampridine-SR, the risk of unfavorable results from future studies of
Fampridine-SR, Acorda Therapeutics' ability to successfully market and
sell Fampridine-SR, if approved, and Zanaflex Capsules, competition,
failure to protect its intellectual property or to defend against the
intellectual property claims of others, the ability to obtain additional
financing to support Acorda Therapeutics' operations, and unfavorable
results from its preclinical programs. These and other risks are
described in greater detail in Acorda Therapeutics' filings with the
Securities and Exchange Commission. Acorda Therapeutics may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Acorda Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
Acorda Therapeutics
Jeff Macdonald, 914-347-4300 ext. 232
jmacdonald@acorda.com
